Previous 10 | Next 10 |
home / stock / rhhbf / rhhbf news
2024-03-08 09:23:14 ET More on Regenxbio REGENXBIO Inc. (RGNX) Q4 2023 Earnings Call Transcript Regenxbio: Robust Data, Decent Cash, Never Ending Trials, Buying At Dips Regenxbio stock jumps 13% on positive data for DMD drug Regenxbio Q4 2023 Earnings Preview...
2024-03-05 09:57:44 ET More on Alnylam Pharmaceuticals Alnylam Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2023 Earnings Call Transcript Alnylam's Huge Opportunity Alnylam posts Q4 topline miss;...
2024-02-26 03:52:17 ET Summary Roche's financial performance in 2023 showed growth despite the decline in COVID-related sales. The company achieved significant milestones, including US approval for Vabysmo, US review for Xolair, and EU approval for a subcutaneous form of Tecentriq...
2024-02-23 17:58:23 ET Summary Ionis Pharmaceuticals, Inc. reported Q4 2023 earnings this week - revenues increased 34% year-on-year to $788m, comfortably outperforming management's guidance. The stock price of Ionis has dipped in 2024 after a lengthy bull run - current market cap...
2024-02-23 12:31:39 ET Summary Prothena Corporation plc has an update coming on the phase 1 study using PRX012 for the treatment of patients with Alzheimer's Disease, expected in 2024. Company is already in the process of exploring the use of PRX012 for the treatment of patients w...
2024-02-16 07:38:34 ET More on Sarepta Therapeutics Sarepta Therapeutics: Leading The Way In DMD Treatment With Gene Therapy Innovations Sarepta Therapeutics: Navigating Elevidys Towards FDA Approval BMO start Sarepta at overweight, sees significant uptake for Elevid...
2024-02-14 21:40:00 ET Summary Tweedy, Browne Company LLC provides investment advisory services. The Company offers portfolio management, financial planning, and consulting services for individuals, institutions, partnerships, pension and profit-sharing plans, charitable foundations, ...
2024-02-11 07:04:47 ET Summary Roche is a well-recognized pharmaceutical company with a strong international presence and a market capitalization of CHF 187 billion. Despite recent challenges, Roche's 2024 guidance shows potential for mid-single-digit growth in revenues and EPS, m...
2024-02-11 04:27:27 ET Summary Ocular Therapeutix is using its Elutyx technology to develop drug candidates for eye disorders, with upcoming results from the HELIOS study for diabetic retinopathy Q2 2024. The company is also progressing with the phase 3 SOL study for wet age-relat...
2024-02-09 02:51:35 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...
News, Short Squeeze, Breakout and More Instantly...
Economist Impact report, Advancing the frontier of health and technology integration: The 2023 Digital Health Barometer highlights opportunities in digitalisation of healthcare Canada NewsWire The report shows digital health technologies demonstrate value, yet integrating th...
Development in Alzheimer's disease diagnosis in Canada: New tests help patients and caregivers make timely decisions Canada NewsWire Roche's Cerebrospinal Fluid (CSF) assays address unmet needs in the detection of amyloid pathology by offering greater accessibility and support...